Evidence map›Paper›PMID 37318620›Full record

ArticleInflammation2023

Role of Myeloperoxidase in ROS Generation and Inflammation Response on Prostate Epithelial Cells.

Thierry Roumeguère, Caroline Noyon, Pierre Van Antwerpen, Philippe Poelvoorde, Isabelle Bar, Fadi Abdulsater, Alexandre Rousseau, Cédric Delporte, Luc Vanhamme, Michel Vanhaeverbeek and 2 more

Open access · greenAbstract read
PubMed Publisher
In one paragraph

Article in Inflammation, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Frontiers in bioengineering and biotechnology · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Thierry Roumeguère *Laboratory of Experimental Medicine, Unit 222, ULB, CHU Charleroi, Charleroi, Belgium. Thierry.roumeguere@erasme.ulb.ac.be.ORCID http://orcid.org/0000-0002-5377-8137
Caroline Noyon *Laboratory of Pharmaceutical Chemistry and Analytical Platform of the Faculty of Pharmacy, ULB, Brussels, Belgium.
Pierre Van AntwerpenLaboratory of Pharmaceutical Chemistry and Analytical Platform of the Faculty of Pharmacy, ULB, Brussels, Belgium.
Philippe PoelvoordeInstitut de Pathologie et de Génétique, Gosselies, Belgium.
Isabelle BarInstitut de Pathologie et de Génétique, Gosselies, Belgium.
Fadi AbdulsaterInstitut de Pathologie et de Génétique, Gosselies, Belgium.
Alexandre RousseauLaboratory of Experimental Medicine, Unit 222, ULB, CHU Charleroi, Charleroi, Belgium.
Cédric DelporteLaboratory of Pharmaceutical Chemistry and Analytical Platform of the Faculty of Pharmacy, ULB, Brussels, Belgium.
Luc VanhammeInstitute for Molecular Biology and Medicine, ULB, Gosselies, Belgium.
Michel VanhaeverbeekLaboratory of Experimental Medicine, Unit 222, ULB, CHU Charleroi, Charleroi, Belgium.
Paul DelreeInstitut de Pathologie et de Génétique, Gosselies, Belgium.
Karim Zouaoui BoudjeltiaLaboratory of Experimental Medicine, Unit 222, ULB, CHU Charleroi, Charleroi, Belgium.
Institute of Pathology and Genetics · BEGrand Charleroi Hospital · BEErasmus Hospital · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Myeloperoxidase (MPO) has been reported in prostate tissue, and considering its pro-oxidant properties, this location might be linked to prostate pathology. The possibility that the glandular prostatic tissue might be the source of MPO and its potential inflammatory effects must be tested. Human prostate material was obtained from prostate biopsies and radical prostatectomies. Immunohistochemistry was performed using MPO-specific human antibody. In situ hybridization using MPO-specific probes and laser-assisted microdissection for quantitative real-time RT-PCR were performed to observe whether MPO is being produced in prostate tissue. Mass spectrometry on prostate biopsies was used to detect products of MPO activity in nucleic acids (DNA/RNA). MPO contribution to intracellular accumulation of ROS and interleukin-8 in prostatic epithelial cells was monitored in vitro. Immunohistochemistry confirmed cellular localization of MPO in epithelial cells of the prostate. The staining varied from light to high intensity. In situ hybridization did not address the presence of mRNA coding for MPO. No MPO-specific modifications on nucleic acids were detected. Mox-LDL was a major factor inducing ROS and cytokines production in prostatic epithelial cells. We did not demonstrate that MPO was synthetized by prostatic epithelial cells. However, in vitro experiments showed the ability of MPO to potentiate the ROS production and inflammation on prostate epithelial cells. Results do not allow us to demonstrate a role of MPO in prostate to date but further studies are mandatory to focus on the potential impact of MPO in the development of prostatic diseases.

Indexed as

PeroxidaseProstateEpithelial CellsHumansMaleReactive Oxygen SpeciesRNA, MessengerPeroxidaseReactive Oxygen SpeciesRNA, Messengerinflammationin situ synthesisMPOoxidative stressprostate

Identifiers

PMID37318620
OpenAlexW4380730844

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.